Compare Amylx Pharmaceuticals Inc (AMLX) vs VICI Properties Inc (VICI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs VICI Properties Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while VICI Properties Inc trades at $26.11 (market cap $28.64B). The key difference: VICI Properties Inc is far larger — about 14.5× Amylx Pharmaceuticals Inc's market cap, and VICI Properties Inc pays a 6.92% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | VICI | |
|---|---|---|
Market Cap | $1.98B | $28.64B |
Sector | Health | Real Estate |
52-Week High | $18.70 | $33.93 |
52-Week Low | $7.64 | $25.94 |
Enterprise Value | $1.70B | $45.86B |
Dividend Yield | — | 6.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
VICI Properties trades at $26.01, showing modest daily gains. The stock is technically bearish with key support at $25, while fundamentals remain strong with a P/E of 8.91 and robust profitability margins. Recent news highlights concerns over tenant concentration but also underscores the REIT's investment-grade balance sheet and attractive 6.8% dividend yield. Q2 2026 earnings are anticipated on July 29, 2026.
The outlook is mixed: strong cash flows and analyst buy ratings support upside to a $30.75 target, but technical weakness and reliance on Caesars/MGM pose risks. Investors may find value in the discounted valuation if operational stability persists amid sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
